Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Drops By 30.1%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 57,400 shares, a decrease of 30.1% from the May 15th total of 82,100 shares. Approximately 1.1% of the company’s shares are sold short. Based on an average daily trading volume, of 64,800 shares, the short-interest ratio is presently 0.9 days.

Alzamend Neuro Stock Down 19.8 %

Shares of Alzamend Neuro stock opened at $0.45 on Friday. The company’s fifty day simple moving average is $0.65 and its two-hundred day simple moving average is $0.85. Alzamend Neuro has a 12-month low of $0.44 and a 12-month high of $10.65. The firm has a market cap of $3.35 million, a PE ratio of -0.46 and a beta of 0.09.

Alzamend Neuro (NASDAQ:ALZN) last posted its earnings results on Monday, March 25th. The company reported ($0.38) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC acquired a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned 0.38% of Alzamend Neuro at the end of the most recent quarter. Institutional investors own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.